ACVR1 and fibrodysplasia ossificans progressiva: Activation of FOP-mutant ACVR1 in response to antibody-mediated dimerization mimics the response to activin A. More importantly, these results indicate that anti-ACVR1 antibodies should not be considered as a therapeutic strategy in FOP.